| Autor: |
Ruggeri, Annalisa, Voza, Antonio, Liberatore, Carmine, Catalano, Gloria, Corrado, Francesco, Di Filippo, Luigi, Nitti, Rosamaria, Fedeli, Carlo, Bruno, Alessandro, Calabretta, Eleonora, Giglio, Fabio, Sciutti, Fabio, Lunghi, Francesca, Landoni, Giovanni, Richardson, Paul G., Iacobelli, Massimo, Aghemo, Alessio, Rovere-Querini, Patrizia, Assanelli, Andrea A., Peccatori, Jacopo, Ciceri, Fabio, Carlo-Stella, Carmelo |
| Zdroj: |
Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p672-672, 1p |
| Abstrakt: |
Background: The clinical spectrum of COVID-19 ranges from pauci-symptomatic forms to severe disease characterized by respiratory failure requiring mechanical ventilation and intensive care unit (ICU) management, as well as multisystem involvement characterized by sepsis, organ dysfunction and death. Treatment of COVID-19 is not standardized, and respiratory failure from ARDS is the leading cause of mortality; in-hospital mortality at 28-days in our tertiary care center in Lombardia, northern Italy was 23% during the first wave in 2020(Ciceri et al. 2020). Endothelial damage and thrombo-inflammation have been identified as common to both COVID-19 pathophysiology and veno-occlusive disease (VOD/SOS). Defibrotide (DF) has endothelial-protective properties, with pro-fibrinolytic, anti-thrombotic, anti-ischemic, anti-inflammatory, and anti-adhesive activity, but no significant systemic anticoagulant effects and is approved for the treatment of severe VOD/SOS. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
